Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Lexicon Pharmaceuticals (LXRX) Leases (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Leases for 3 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 51.45% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 51.45% increase, with the full-year FY2025 number at $7.3 million, up 51.45% from a year prior.
  • Leases was $7.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $7.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.5 million in Q3 2025 to a low of $4.5 million in Q2 2025.
  • A 3-year average of $5.6 million and a median of $5.3 million in 2024 define the central range for Leases.
  • Biggest YoY gain for Leases was 51.45% in 2025; the steepest drop was 14.81% in 2025.
  • Lexicon Pharmaceuticals' Leases stood at $5.5 million in 2023, then dropped by 12.15% to $4.8 million in 2024, then surged by 51.45% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Leases are $7.3 million (Q4 2025), $7.5 million (Q3 2025), and $4.5 million (Q2 2025).